Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics, Inc. completed enrollment of the IgA nephropathy (IgAN) cohort in its Phase 2 basket study of vensobafusp alfa (KP104). Stage 1 enrolled 18 patients across three cohorts: an induction regimen followed by subcutaneous maintenance dosing at Q2W, Q4W or Q8W, with six patients in each cohort. Stage 1 is intended to assess safety, tolerability and initial efficacy and help determine dose levels for further evaluation.
Jasper expects initial interim IgAN data by year-end 2026. The study is evaluating vensobafusp alfa for efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics in China across renal diseases including IgAN, complement 3 glomerulopathy (C3G) and focal segmental glomerulosclerosis (FSGS). Jasper announced an additional FSGS cohort, with the first patient anticipated to be dosed in the first quarter of 2027. Vensobafusp alfa is investigational and has not been approved for any indication by any health authority.
Jasper Therapeutics, Inc. (JSPR) registered for resale up to 284,013,011 shares of common stock issuable upon conversion of 4,655,951 shares of PIPE preferred stock. Each preferred share converts into 61 common shares on the third business day after stockholder approval, subject to beneficial ownership limits. Jasper will receive no proceeds from selling stockholders’ sales; the selling stockholders receive the proceeds, while Jasper bears registration costs. Jasper says sales of substantial amounts could depress its share price and affect its ability to raise equity capital.
Jasper acquired Kira Pharmaceuticals on July 16, 2026, and a separate private placement closed on July 20, 2026, for approximately $132.0 million in gross proceeds. The company reported an accumulated deficit of $320.6 million as of June 30, 2026, and concluded substantial doubt exists about its ability to continue as a going concern within one year from filing its quarterly report for that period. Jasper said it is actively seeking additional capital and may delay, reduce or eliminate research and development programs if it cannot obtain adequate financing when needed or on acceptable terms.
Jasper Therapeutics, Inc. seeks approval to issue common shares upon conversion of preferred stock from its completed Kira acquisition and $132,000,000 PIPE financing, ratification of Patrick Crutcher’s appointment as a director, and adjournment if needed. The acquisition closed July 16, 2026; the financing closed July 20, 2026.
Full conversion and exercise could issue 320,289,040 common shares for merger securities and options and 284,013,011 for the PIPE, totaling 604,302,051. The total is approximately 95% of the 33,274,561 common shares outstanding on September 28, 2026, on an as-converted basis. Conversion requires stockholder approval and is subject to beneficial-ownership limits; each preferred share is currently convertible into 61 common shares, subject to adjustment.
If conversion proposals fail, the relevant preferred stock remains unconvertible and Jasper must continue seeking approval; specified failures to deliver conversion shares can trigger cash settlement. Nasdaq notices said Jasper no longer met the $1.00 bid-price and $2,500,000 equity requirements. Jasper submitted an equity compliance plan and expects a reverse split before the November 30, 2026 bid-price deadline, but gives no assurance of regaining compliance; the approved 1-for-15 to 1-for-35 range has not been effected or assigned a ratio.
Jasper Therapeutics, Inc. (JSPR) commenced an offer to purchase any and all outstanding Warrants issued in its September 18, 2025 underwritten public offering for $0.324 in cash per Warrant, without interest. Each Warrant entitles its holder to purchase one share of common stock at an exercise price of $2.92, subject to adjustment. There were 12,345,707 Warrants outstanding as of October 6, 2026.
The offer is scheduled to remain open until one minute after 11:59 p.m. Eastern Time on November 6, 2026, unless Jasper extends it or terminates it earlier. Holders may withdraw tendered Warrants before expiration and exercise Warrants during the offer. Warrants tendered and accepted will be retired and cancelled; untendered Warrants remain outstanding on their original terms and expire at 5:00 p.m. Eastern Time on March 18, 2030. Jasper will pay for Warrants validly tendered and not withdrawn promptly after expiration. If all outstanding Warrants are tendered, Jasper expects to pay approximately $4.0 million from cash on hand. The offer is subject to customary conditions.
Jasper Therapeutics, Inc. (JSPR) is offering to purchase for cash any and all of its outstanding Warrants at $0.324 per Warrant, without interest. As of October 6, 2026, 12,345,707 Warrants were outstanding. Each Warrant entitles its holder to purchase one share of common stock at an exercise price of $2.92 per share, subject to adjustments. The offer is subject to the terms and conditions in the Offer to Purchase and related Letter of Transmittal. Warrants validly tendered and accepted for purchase will be cancelled by the company.
Jasper Therapeutics, Inc. stockholders approved three proposals at the September 30, 2026 special meeting. The reverse stock split proposal authorizes the Board, in its sole discretion, to effect a split at any time on or before December 31, 2026, at a ratio from 1-for-15 to 1-for-35 (or any number in between), without reducing authorized common shares. Stockholders also approved an increase in authorized common shares from 490,000,000 to 675,000,000, to be effected in the Board’s sole discretion.
The proposals received 21,088,353 votes for the reverse split, 20,722,644 votes for the share increase, and 20,938,915 votes for adjournment. At the meeting, 21,747,865 shares were represented, approximately 65.36% of the 33,274,561 common shares issued and outstanding as of August 10, 2026.
Jasper Therapeutics, Inc. refiled its unaudited pro forma information for its acquisition of Kira Pharmaceuticals, completed July 16, 2026. Jasper issued Kira shareholders 5,195,009 voting common shares and 4,644,977 non-voting convertible preferred shares; each preferred share converts into 61 common shares, subject to certain conditions. Jasper accounted for the merger as an asset acquisition and recognized no goodwill.
The preferred-stock financing closed July 20, 2026, with 4,655,951 shares sold for approximately $132.0 million. Each common-stock holder of record immediately before the merger closing was entitled to one contingent value right per share; holders may receive a pro-rata portion of $30.0 million if the U.S. Food and Drug Administration issues a Priority Review Voucher for briquilimab on or before December 31, 2028. Jasper acquired the rights and receivables under Kira's Mirador license, under which Mirador agreed to pay $12.0 million upfront and $8.0 million upon delivery of drug substance and compound, plus potential development milestones up to $108.5 million, commercial milestones up to $350.0 million and tiered royalties. Unaudited pro forma combined net loss was $7.352 million for the six months ended June 30, 2026 and $206.837 million for the year ended December 31, 2025; these illustrative figures exclude anticipated synergies, operating efficiencies and cost savings.
Jasper Therapeutics, Inc. amended its report on the completed July 16, 2026 acquisition of Kira Pharmaceuticals, adding Kira’s audited 2025 and 2024 statements, unaudited results for the six months ended June 30, 2026 and 2025, and pro forma combined financial information. Kira recorded a $3.418 million net loss and $3.451 million operating cash outflow in the first half of 2026, compared with a $1.161 million net loss and $648,000 operating cash outflow a year earlier. Its accumulated deficit was $184.2 million as of June 30, 2026; Kira’s auditors cited substantial doubt about its ability to continue as a going concern.
Jasper completed a concurrent private placement of approximately 4.7 million non-voting convertible preferred shares for $132.0 million in gross proceeds. Jasper agreed to seek a stockholder vote on conversion within 120 days after closing; if approval is not obtained within 12 months, holders may require repurchase at then-current fair market value. Under Kira’s July 13, 2026 Mirador license, Kira is entitled to $12.0 million upfront and $8.0 million upon delivery, may receive up to $458.5 million in development, regulatory and commercial milestones, and may receive tiered royalties on future net sales.
Jasper Therapeutics, Inc. (JSPR) said Herb Cross submitted his resignation on September 23, 2026, effective October 9, 2026, from his roles as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary, citing other professional endeavors. The board appointed Jeet Mahal, the company’s President and Chief Executive Officer, as interim Principal Financial Officer; Rick Ruiz, Vice President, Finance, as interim Principal Accounting Officer; and Matthew Ros, Chief Operating Officer, as interim Corporate Secretary. Each appointment takes effect when Cross’s resignation becomes effective. Ruiz joined Jasper in 2024 and has over 25 years of finance and accounting experience; he received no equity awards in connection with his promotion.
Jasper Therapeutics, Inc. is the issuer of redeemable warrants named in Nasdaq Stock Market LLC’s notification of removal from listing and/or registration. Nasdaq stated that it complied with its rules to strike the warrant class from listing and/or withdraw its registration. The warrants are exercisable in groups of ten for one share of Voting Common Stock at an exercise price of $115.00.